证券代码：688222 证券简称：成都先导 公告编号：2025-045 成都先导药物开发股份有限公司 关于选举董事长、副董事长、董事会专门委员会委员 暨聘任高级管理人员及证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 9 月 15 日成都先导药物开发股份有限公司（以下简称"公司"或"成 都先导"）召开 2025 年第一次临时股东大会，选举产生了公司第三届董事会 5 名非独立董事、3 名独立董事，2025 年 9 月 5 日公司召开 2025 年第二次职工代 表大会并经公示，选举产生了 1 名职工代表董事，共同组成了公司第三届董事会。 2025 年 9 月 15 日，公司召开第三届董事会第一次会议，选举产生了新一届董事 会董事长、副董事长、专门委员会委员，并聘任新一届高级管理人员及证券事务 代表。现就相关情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 9 月 15 日，公司召开 2025 年第一次临时股东大会，该次股东大会 采用累积投票制的方式选举 JIN LI（李 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-049 成都先导药物开发股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三）会议召开方式：上证路演中心网络互动 重要内容提示： 投资者可于 2025 年 09 月 16 日（星期二）至 09 月 22 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 投资者关系邮箱（investors@hitgen.com）进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）披露公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 09 月 23 日（星期二） 14:00-15:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进 行交流。 一、说明会 ...

成都先导药物开发股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票 激励计划激励对象名单（截至授予日）的核查意见 （三）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； （四）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （五）法律法规规定不得参与上市公司股权激励的； （六）中国证监会认定的其他情形。 四、本次授予激励对象包括公司实际控制人 JIN LI，除前述人员外，本次授 予激励对象不包括公司实际控制人的配偶、父母、子女、公司其他单独或合计持 有上市公司 5%以上股份的股东及其配偶、父母、子女，亦不包括公司独立董事。 成都先导药物开发股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）《科创板上 市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性 文件和《成都先导药物开发股份有限公司章程》（以下简称"《公 ...

Group 1 - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. experienced a decline of 5.03% on September 4, with a stock price of 27.35 yuan per share, a trading volume of 1.031 billion yuan, a turnover rate of 8.94%, and a total market capitalization of 10.959 billion yuan [1] - The company, established on February 22, 2012, and listed on April 16, 2020, is located in Chengdu Tianfu International Biological City and specializes in early-stage drug discovery services using its core DEL technology, with 99.95% of its revenue coming from new drug development services [1] Group 2 - According to data from the top ten holdings of funds, one fund under Furong Fund holds a significant position in Chengdu Xian Dao, with the Furong Medical Health Mixed Fund A (015655) holding 16,200 shares, accounting for 2.01% of the fund's net value, making it the sixth-largest holding [2] - The Furong Medical Health Mixed Fund A was established on June 28, 2022, with a latest scale of 11.8186 million, yielding a return of 14.22% this year, 10.55% over the past year, and a loss of 20.8% since inception [2]

证券代码：688222 证券简称：成都先导 公告编号：2025-040 成都先导药物开发股份有限公司 监事会关于公司 2025 年限制性股票激励计划拟激励对象名 单的核查意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年月 8 月 26 日，成都先导药物开发股份有限公司（以下简称"公司"） 第二届董事会第二十三次会议、第二届监事会第十七次会议审议通过了《关于公 司<2025 年限制性股票激励计划（草案）>及其摘要的议案》，根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市 规则》等相关规定，对《公司 2025 年限制性股票激励计划(草案)》(以下简称"《激 励计划（草案）》"、"本激励计划")中拟激励对象的姓名和职务在公司内部进行 了公示。公司监事会结合公示情况对本激励计划拟激励对象名单进行了核查，相 关公示情况及核查意见如下： 一、公示情况及核查方式 （一）公司对激励对象的公示情况 1、公示内容：拟激励对象的姓名和职务 2、公示时间：2025 年 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-040 成都先导药物开发股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划拟激励对象名单的核查意见及公示情况说明 本公司董事会薪酬与考核委员会及全体委员保证本公告内容不存在任何虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 2025 年月 8 月 26 日，成都先导药物开发股份有限公司（以下简称"公司"） 第二届董事会第二十三次会议、第二届监事会第十七次会议审议通过了《关于公 司<2025 年限制性股票激励计划（草案）>及其摘要的议案》，根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市 规则》等相关规定，对《公司 2025 年限制性股票激励计划(草案)》(以下简称"《激 励计划（草案）》"、"本激励计划")中拟激励对象的姓名和职务在公司内部进行 了公示。公司董事会薪酬与考核委员会结合公示情况对本激励计划拟激励对象名 单进行了核查，相关公示情况及核查意见如下： 一、公示情况及核查方式 （一）公司对激励对象的公示情况 3、公示方式：公 ...

Group 1 - The company achieved revenue of 227 million yuan in H1 2025, representing a growth of 16.58%, and a net profit attributable to shareholders of 50 million yuan, up 390.72% [1] - In Q2 alone, the company reported revenue of 120 million yuan, an increase of 37.71%, and a net profit attributable to shareholders of 22 million yuan, up 681.39% [1] - The overall gross margin for H1 2025 was 53.81%, an increase of 7.18 percentage points, and the net profit margin was 21.82%, up 17.05 percentage points, indicating a strong recovery in profitability [2] Group 2 - The DEL business segment continued to grow rapidly, with revenue of 102 million yuan in H1 2025, an increase of 40.45%, driven mainly by the growth of customized library services [2] - The company is advancing in new drug discovery and optimization through its DEL+AI/ML projects, achieving significant milestones in model and data development, high-throughput chemical platforms, and project pipelines [3] - The company has initiated two self-developed projects based on the HAILO platform, which have entered the evaluation stage for lead compounds [3] Group 3 - Revenue projections for the company from 2025 to 2027 are estimated at 507 million yuan, 609 million yuan, and 735 million yuan, with year-on-year growth rates of 18.83%, 20.10%, and 20.65% respectively [4] - The net profit attributable to shareholders is expected to be 78 million yuan, 111 million yuan, and 136 million yuan for the same period, with growth rates of 52.32%, 41.88%, and 22.47% respectively [4]

Group 1 - The core point of the announcement is that Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd. has reduced its shareholding in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. by 1% from 11.17% to 10.92% through a centralized bidding process, involving the sale of 1 million shares [1][2] - The reduction in shareholding is part of a previously disclosed plan and does not trigger a mandatory tender offer, as it is conducted by a shareholder holding more than 5% but not the largest shareholder [1][2] - The company will ensure that Huabo Medical Device adheres to relevant regulations during the share reduction period and will keep investors informed of any updates [2]

Core Points - The major shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd., has reduced its stake in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. from 11.17% to 10.92%, triggering a 1% threshold change [1][2] - The reduction in shareholding occurred between August 29, 2025, and September 3, 2025, with a total of 100,000 shares sold [1] - The company confirmed that this change does not violate any prior commitments or plans and does not trigger mandatory tender offer obligations [1][2] Shareholder Information - The shareholder involved in the equity change is Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd., which is classified as a significant shareholder [1] - The company has no controlling shareholder or actual controller, and the shareholder does not have any concerted action parties [1] Regulatory Compliance - The equity change does not require the disclosure of an equity change report as per relevant laws and regulations [2] - The company has adhered to the relevant reduction regulations and has timely disclosed the necessary information to investors [2]

Market Overview - On September 4, the medical services sector declined by 4.28%, with Bid Pharma leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the medical services sector included: - Zihua Pharmaceutical (600721) with a closing price of 11.07, up 6.24% [1] - Innovation Medical (002173) with a closing price of 24.99, up 5.31% [1] - Wisdom Pharmaceutical (300149) with a closing price of 13.17, up 4.36% [1] - Major decliners included: - Bid Pharma (688073) with a closing price of 62.65, down 9.44% [2] - WuXi AppTec (603259) with a closing price of 101.94, down 8.06% [2] - Zhaoyan New Drug (603127) with a closing price of 30.92, down 7.48% [2] Capital Flow - The medical services sector experienced a net outflow of 1 billion yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2][3] - Key stocks with significant capital flow included: - Innovation Medical (002173) with a net inflow of 136 million yuan from institutional investors [3] - Wisdom Pharmaceutical (300149) with a net inflow of 79 million yuan from institutional investors [3] - Meinian Health (002044) with a net inflow of 64 million yuan from institutional investors [3]